Miltenyi Biomedicine GmbH
3 clinical trials · 3 recruiting · INDUSTRY
Trials by Miltenyi Biomedicine GmbH
RECRUITINGPhase 2NCT07288879
DALY II Japan/MB-CART2019.1 for DLBCL
DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with...
Sponsor: Miltenyi Biomedicine GmbHEnrolling: 315 locations
DLBCL - Diffuse Large B Cell LymphomaCAR T Cell Therapy
RECRUITINGPhase 1 / Phase 2NCT06189157
MB-CART19.1 in Refractory SLE
This is a phase l/ll open-label, multicentre, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE systemic lupus erythematosus. In the phase I part, a...
Sponsor: Miltenyi Biomedicine GmbHEnrolling: 293 locations
SLE - Systemic Lupus Erythematosus
RECRUITINGPhase 1 / Phase 2NCT06347718
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered...
Sponsor: Miltenyi Biomedicine GmbHEnrolling: 241 location
Systemic Lupus ErythematosusSystemic SclerosisDermatomyositis+1